Tag: breast cancer
Where postmenopausal hormone therapy stands today
Amos Pines
A dramatic change has occurred over the past decade with regard to the use of hormones during the postmenopausal period. In the 90’s, the belief in the USA being that there was reason to recommend hormone therapy (HT) for the prevention of coronary artery disease, the guidelines of the American College of Physicians in 1992 were as follows …
Metformin: Its emerging role in oncology
Dragan Micic, Goran Cvijovic, Vladimir Trajkovic, Leonidas H. Duntas, Snezana Polovina
Metformin is considered, in conjunction with lifestyle modification, as a first-line treatment modality for type 2 diabetes mellitus (DM). Recently, several clinical studies have reported reduced incidence of neoplastic diseases in DM type 2 patients treated with metformin, as compared to diet or other antidiabetic agents …
Lack of association between Hashimoto thyroiditis and breast cancer: A quantitative research synthesis.
Nicholas J. Sarlis, Loukas Gourgiotis, Frank Pucino, George J. Tolis
Several authors have suggested a positive association between Hashimoto thyroiditis (HT) and breast cancer (BrCa). Others have refuted these findings; hence, this subject remains controversial. We therefore reviewed the world literature on this subject accumulated over the last 50 years and performed a quantitative research synthesis …
Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy
Eftychia Chala, Christos Manes, Helias Iliades, Georgios Skaragkas, Despina Mouratidou, Efthymios Kapantais
OBJECTIVE: To evaluate insulin values, insulin resistance, growth factors and cytokine levels in women suffering from breast cancer and the effect of chemotherapy on these parameters. DESIGN: In a prospective study, glucose and insulin values were determined in ten previously undiagnosed diabetic postmenopausal women with stage IV breast cancer (hepatic metastases excluded) during an oral glucose tolerance test …
Calcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single dose of denosumab: a pilot study
Konstantinos Toulis, Paschalia Iliadou, Stylianos Mandanas, Polyzo Kazila, Efterpi Margaritidou, Konstantinos Georgopoulos, Kalliopi Pazaitou-Panayiotou
Along with achieving a reduction in the incidence of osteoporotic fractures, denosumab (a human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) causes conformational changes in the calcium-sensing receptor (CaSR), leading to parathyroid hormone exocytosis …